Although CNAs are an important event involved in tumorigenesis, their detection in clinical cancer genetics labs is generally limited to few cytogenetic-based assays focusing on gains of a single gene, such as ERBB2 used to determine breast cancer patient’s suitability for targeted therapy46. Here, ERBB2 is linked to cancer.